Population Pharmacokinetic Model of Platinum Disposition in Cancer Patients Receiving Cisplatin and Randomized to 5‐HT 3 Antagonist Antiemetic Drugs
The Journal of Clinical Pharmacology · 2025
DOI: 10.1002/jcph.6177 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Pharmacology, 2025. Verfasst von Lauren E Thompson und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora,…. Hauptthemen laut MEDLINE: Cisplatin, Antiemetics, Serotonin 5-HT3 Receptor Antagonists, Neoplasms. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NIEHS NIH HHS, NIGMS NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Cisplatin is a platinum‐based chemotherapeutic drug used to treat many types of cancer. The aim of this study was to develop a population pharmacokinetic model that incorporates plasma unbound and bound platinum levels. Cancer patients undergoing their first or second cycle of cisplatin‐containing chemotherapy (n = 33) were prospectively randomized to receive a 5‐hydroxytryptamine (5‐HT 3 ) antagonist (5‐HT 3 A) antiemetic (ondansetron, granisetron, or palonosetron) followed by blood collection over 10 days. Total and unbound platinum levels were quantified using inductively coupled plasma mass spectrometry. Plasma concentrations of bound and unbound platinum were used to develop a nonlinear mixed‐effect pharmacokinetic model in Phoenix NLME (v8.3, Certara Inc.). A stepwise search was used to screen covariates that influenced pharmacokinetic parameters. A compartment for bound platinum was added to a two‐compartment unbound platinum model to create a combined platinum model. The volume of the central compartment for unbound platinum (V1_u) was significantly impacted by previous cisplatin exposure and the intercompartmental clearance of unbound platinum (CL2_u) was significantly influenced by concomitant lorazepam use. The models also suggested ondansetron‐ and granisetron‐treated subjects had a 331% and 114% increase, respectively, in circulating exposures to unbound platinum than palonosetron‐treated subjects. The results suggest platinum pharmacokinetics are altered by concomitant 5‐HT 3 A antiemetic use, concomitant lorazepam use, and previous exposure to cisplatin. Ondansetron and granisetron co‐treatment increased unbound platinum exposure compared to palonosetron co‐treatment, suggesting that palonosetron may be a preferred 5‐HT 3 A to reduce the risk of cisplatin‐induced kidney injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
- Environmental and Occupational Health Sciences Institute, Rutgers University, Piscataway, NJ, USA.
- Department of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ, USA.
- Department of Earth and Planetary Sciences, Rutgers University, Piscataway, NJ, USA.
- Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
- Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
ORCID-Profile: Lauren E Thompson
Förderung
- NCATS NIH HHS
- NIEHS NIH HHS
- NIGMS NIH HHS
- NCI NIH HHS
- NIDDK NIH HHS
- National Cancer Institute
- National Institute of General Medical Sciences
- National Center for Advancing Translational Sciences
Zitieren
APA
Thompson, L. E., Ghimire, A., Wen, X., Kim, C., Doherty, C. L., Buckley, B. T., Bowles, D. W., O'Bryant, C. L., Jaimes, E. A., Aleksunes, L. M., & Joy, M. S. (2025). Population Pharmacokinetic Model of Platinum Disposition in Cancer Patients Receiving Cisplatin and Randomized to 5‐HT 3 Antagonist Antiemetic Drugs. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.6177
Vancouver
Thompson LE, Ghimire A, Wen X, Kim C, Doherty CL, Buckley BT, et al. Population Pharmacokinetic Model of Platinum Disposition in Cancer Patients Receiving Cisplatin and Randomized to 5‐HT 3 Antagonist Antiemetic Drugs. The Journal of Clinical Pharmacology. 2025. doi:10.1002/jcph.6177
BibTeX
@article{Thompson2025,
author = {Thompson, Lauren E and Ghimire, Avisek and Wen, Xia and Kim, Christine and Doherty, Cathleen L and Buckley, Brian T and Bowles, Daniel W and O'Bryant, Cindy L and Jaimes, Edgar A and Aleksunes, Lauren M and Joy, Melanie S},
title = {Population Pharmacokinetic Model of Platinum Disposition in Cancer Patients Receiving Cisplatin and Randomized to 5‐HT 3 Antagonist Antiemetic Drugs},
journal = {The Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/jcph.6177}
}
EUVIMED